Principia Biopharma, Inc. (PRNB)


Stock Price Forecast

Sept. 25, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Principia Biopharma, Inc. chart...

About the Company

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

103

CEO

Martin Babler

Exchange

NASDAQ

Website

http://www.principiabio.com

$50M

Total Revenue

103

Employees

$3B

Market Capitalization

-40.51

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PRNB News

Hedge Funds Keep Buying Principia Biopharma Inc. (PRNB)

1y ago, source: AOL

With this in mind, let’s examine the smart money sentiment towards Principia Biopharma Inc. (NASDAQ:PRNB) and determine whether hedge funds skillfully traded this stock. Video: Watch our video ...

Sanofi to Acquire Principia Biopharma for $3.7 billion; Analysts Optimistic on Outlook

3y ago, source: FXEmpire.com

Principia Biopharma stock forecast Six analysts forecast the average price in 12 months at $112.83 with a high forecast of $130.00 and a low forecast of $100.00.

Investors put skin in Peninsula biotech's psoriasis game, and it delivers results

6d ago, source:

Alumis' target is TYK2, or tyrosine kinase 2, a central player in immune signaling and inflammatory signaling pathways.

Sanofi Agrees to Pay $2.9 Billion For Provention Bio

1y ago, source: Hosted on MSN

The acquisition would be Sanofi’s biggest since the purchase of Principia Biopharma Inc. for more than $3 billion in 2020. Sanofi would get a new medicine to complement a handful of its older ...

Sanofi to buy US drugmaker in US$3.4bil deal

25d ago, source: The Star

PARIS: Sanofi plans to acquire San Francisco, California-based Principia Biopharma Inc in a deal with an enterprise value of US$3.4bil as the French drugmaker pivots toward innovative therapies to ...

Dow Futures, Barrick Gold, Sanofi, Principia Biopharma - 5 Things You Must Know Monday

3y ago, source: TheStreet.com

Wall Street is coming off its third straight week of gains; Sanofi to acquire U.S. biotech Principia Biopharma; Warren Buffett builds a position in Barrick Gold. Stock futures pointed higher ...

Biopharma company to create 401 jobs in Wilson

on MSN ago, source:

The jobs would be part of a $371 million investment in Wilson County. The announcement came during a meeting of the state ...

Principia vs. Norwood

12d ago, source:

Principia's Dasia Scott (21) goes up for a layup during a girls Class 2 semifinal game on March 6, 2024 at Mizzou Arena on ...

ABVC BioPharma Inc ABVC

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Plc Gsk's Net Worth

6d ago, source: Benzinga.com

Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...

Nexien BioPharma Inc NXEN

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

MORGENTHALER VENTURE PARTNERS IX LP's Net Worth

24d ago, source: Benzinga.com

Who is MORGENTHALER VENTURE PARTNERS IX LP? MORGENTHALER VENTURE PARTNERS IX LP has an estimated net worth of $210 Million. This is based on reported shares across multiple companies, which ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...